drugset / Trial / NCT06981806
Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
This is a single-center, open-label, phase 1 dose escalation and dose expansion (safety confirmation) trial to evaluate the safety and tolerability of balixafortide and cosibelimab in patients with metastatic PDAC who progressed after SOC chemotherapy.
Timeline
- Start
- 2026-01
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Balixafortide | Peptide | 7.5 mg/kg | Intravenous |
| Subject | Balixafortide | Peptide | 11 mg/kg | Intravenous |
| Subject | Balixafortide | Peptide | 16 mg/kg | Intravenous |
| Subject | Cosibelimab | Monoclonal antibody | 800 mg | Intravenous |